{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T03:52:41Z","timestamp":1792036361350,"version":"4.4.0"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"1123","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,7,1]]},"abstract":"<jats:sec>\n                  <jats:title>Objectives:<\/jats:title>\n                  <jats:p>To investigate the efficacy of a schedule of low-dose radiotherapy (LDRT) with 4\u2009Gy (2\u2009Gy x 2) in a cohort of unselected MALT or MZL patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods:<\/jats:title>\n                  <jats:p>We retrospectively collected all patients receiving LDRT, either for cure or palliation, for a stage I\u2013IV histologically proven MALT or MZL between 2016 and 2020. Response to LDRT was evaluated with the Lugano criteria. Local control (LC), distant relapse-free survival (DRFS), progression-free survival (PFS) and overall survival (OS) were stratified for treatment intent (curative vs palliative) and estimated by the Kaplan-Meier product-limit.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results:<\/jats:title>\n                  <jats:p>Among 45 consecutively enrolled patients with a median age of 68 years (range 22\u201386), 26 (58%) were female. Thirty-one patients (69%) with a stage I\u2013II disease received LDRT as first line therapy and with a curative intent. Overall response rate was 93%, with no significant difference among curative and palliative intent. With a median follow-up of 18 months, LC, DRFS, PFS and OS at 2 years were 93, 92, 76 and 91%, respectively, in the overall population. Patients receiving curative LDRT had a better PFS at 2 years (85% vs 54%, p &amp;lt; 0.01) compared to patients receiving palliative treatment. LDRT was well tolerated in all patients, without any significant acute or chronic side-effect.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions:<\/jats:title>\n                  <jats:p>LDRT is effective and well tolerated in patients affected with MALT or nodal MZL, achieving high response rates and durable remission at 2 years.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Advances in knowledge:<\/jats:title>\n                  <jats:p>This study shows the efficacy of LDRT in the treatment of MALT and MZL.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1259\/bjr.20210012","type":"journal-article","created":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T07:16:22Z","timestamp":1623395782000},"source":"Crossref","is-referenced-by-count":14,"title":["Efficacy of low-dose radiotherapy (2 Gy \u00d7 2) in the treatment of marginal zone and mucosa-associated lymphoid tissue lymphomas"],"prefix":"10.1093","volume":"94","author":[{"given":"Marzia","family":"Cerrato","sequence":"first","affiliation":[{"name":"Department of Oncology, University of Torino , Torino , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Orlandi","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Torino , Torino , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelisa","family":"Vella","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Torino , Torino , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Bartoncini","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Torino , Torino , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe C","family":"Iorio","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Torino , Torino , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Bongiovanni","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Torino , Torino , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Capriotti","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Torino , Torino , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carola","family":"Boccomini","sequence":"additional","affiliation":[{"name":"Hematology Unit, Azienda Ospedaliero Universitaria Citt\u00e0 della Salute e della Scienza di Torino , Torino , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Vassallo","sequence":"additional","affiliation":[{"name":"Hematology Unit, Azienda Ospedaliero Universitaria Citt\u00e0 della Salute e della Scienza di Torino , Torino , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Cavallin","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Torino , Torino , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viola","family":"De Luca","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Torino , Torino , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca R","family":"Giglioli","sequence":"additional","affiliation":[{"name":"Medical Physics Unit, A.O.U. Citt\u00e0 della Salute e della Scienza , Torino , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Ricardi","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Torino , Torino , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7668-3296","authenticated-orcid":false,"given":"Mario","family":"Levis","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Torino , Torino , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,6,16]]},"reference":[{"key":"2024050215465234100_b1","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1182\/blood-2015-12-624304","article-title":"The spectrum of malt lymphoma at different sites: biological and therapeutic relevance","volume":"127","author":"Zucca","year":"2016","journal-title":"Blood"},{"key":"2024050215465234100_b2","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1093\/annonc\/mdx025","article-title":"Long-Term outcome of 487 patients with early-stage extra-nodal marginal zone lymphoma","volume":"28","author":"Teckie","year":"2017","journal-title":"Ann Oncol"},{"key":"2024050215465234100_b3","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.radonc.2011.05.013","article-title":"Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial","volume":"100","author":"Lowry","year":"2011","journal-title":"Radiother Oncol"},{"key":"2024050215465234100_b4","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S1470-2045(14)70036-1","article-title":"4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (Fort): a randomised phase 3 non-inferiority trial","volume":"15","author":"Hoskin","year":"2014","journal-title":"Lancet Oncol"},{"key":"2024050215465234100_b5","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0360-3016(01)01626-1","article-title":"A high and sustained response rate in refractory or relapsing low-grade lymphoma masses after low-dose radiation: analysis of predictive parameters of response to treatment","volume":"51","author":"Girinsky","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2024050215465234100_b6","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1016\/S0360-3016(02)03050-X","article-title":"Phase II study of palliative low-dose local radiotherapy in disseminated indolent non-Hodgkin's lymphoma and chronic lymphocytic leukemia","volume":"54","author":"J\u00f3hannsson","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2024050215465234100_b7","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1200\/JCO.2003.09.542","article-title":"High response rates and lasting remissions after low-dose involved field radiotherapy in indolent lymphomas","volume":"21","author":"Haas","year":"2003","journal-title":"J Clin Oncol"},{"key":"2024050215465234100_b8","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ijrobp.2015.01.040","article-title":"Long-Term outcomes and patterns of relapse of early-stage extranodal marginal zone lymphoma treated with radiation therapy with curative intent","volume":"92","author":"Teckie","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2024050215465234100_b9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/hon.2900120102","article-title":"Potential role for low dose limited-field radiation therapy (2 X 2 grays) in advanced low-grade non-Hodgkin's lymphomas","volume":"12","author":"Ganem","year":"1994","journal-title":"Hematol Oncol"},{"key":"2024050215465234100_b10","doi-asserted-by":"crossref","first-page":"e781","DOI":"10.1016\/j.ijrobp.2010.10.013","article-title":"Palliation by low-dose local radiation therapy for indolent non-Hodgkin lymphoma","volume":"81","author":"Chan","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2024050215465234100_b11","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.ijrobp.2010.12.062","article-title":"Low-Dose radiotherapy in indolent lymphoma","volume":"81","author":"Rossier","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2024050215465234100_b12","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ijrobp.2012.12.024","article-title":"Low-Dose involved-field radiation in the treatment of non-Hodgkin lymphoma: predictors of response and treatment failure","volume":"86","author":"Russo","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2024050215465234100_b13","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S1470-2045(20)30686-0","article-title":"4 Gy versus 24 Gy radiotherapy for follicular and marginal zone lymphoma (Fort): long-term follow-up of a multicentre, randomised, phase 3, non-inferiority trial","volume":"22","author":"Hoskin","year":"2021","journal-title":"Lancet Oncol"},{"key":"2024050215465234100_b14","doi-asserted-by":"crossref","first-page":"e385","DOI":"10.1016\/j.ijrobp.2012.01.005","article-title":"Low-Dose radiation treatment in pulmonary mucosa-associated lymphoid tissue lymphoma: a plausible approach? A single-institution experience in 10 patients","volume":"83","author":"Girinsky","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2024050215465234100_b15","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.ijrobp.2013.04.035","article-title":"Low-Dose radiation therapy (2 Gy \u00d7 2) in the treatment of orbital lymphoma","volume":"86","author":"Fasola","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2024050215465234100_b16","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/hed.24717","article-title":"Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma","volume":"39","author":"Pinnix","year":"2017","journal-title":"Head Neck"},{"key":"2024050215465234100_b17","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.jaad.2017.07.053","article-title":"Very low-dose versus standard dose radiation therapy for indolent primary cutaneous B-cell lymphomas: a retrospective study","volume":"78","author":"Goyal","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"2024050215465234100_b18","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.clml.2018.12.016","article-title":"Emerging treatment strategies for primary breast extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue","volume":"19","author":"Ludmir","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2024050215465234100_b19","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.annonc.2019.10.010","article-title":"Marginal zone lymphomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Zucca","year":"2020","journal-title":"Ann Oncol"},{"key":"2024050215465234100_b20","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijrobp.2015.01.009","article-title":"Modern radiation therapy for extranodal lymphomas: field and dose guidelines from the International lymphoma radiation Oncology Group","volume":"92","author":"Yahalom","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2024050215465234100_b21","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ijrobp.2014.01.006","article-title":"Modern radiation therapy for nodal non-Hodgkin lymphoma-target definition and dose guidelines from the International lymphoma radiation Oncology Group","volume":"89","author":"Illidge","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2024050215465234100_b22","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"2024050215465234100_b23","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1182\/blood-2008-12-195453","article-title":"Extranodal marginal zone lymphoma of the ocular adnexa","volume":"114","author":"Stefanovic","year":"2009","journal-title":"Blood"},{"key":"2024050215465234100_b24","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0167-8140(00)00328-5","article-title":"Orbital lymphoma: radiotherapy outcome and complications","volume":"59","author":"Stafford","year":"2001","journal-title":"Radiother Oncol"},{"key":"2024050215465234100_b25","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2020.106443","article-title":"Low-Dose radiotherapy (2\u00d72 G) versus low doses and rituximab in the treatment of marginal zone B-cell lymphoma previously untreated","volume":"98","author":"Aviles","year":"2020","journal-title":"Leuk Res"},{"key":"2024050215465234100_b26","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1080\/10428194.2019.1644333","article-title":"Radiation therapy for salivary gland MALT lymphoma: ultra-low dose treatment achieves encouraging early outcomes and spares salivary function.","volume":"61","author":"Gunther","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"2024050215465234100_b27","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1002\/cam4.2796","article-title":"Repeated courses of low-dose 2 \u00d7 2 Gy radiation therapy in patients with indolent B-cell non-Hodgkin lymphomas","volume":"9","author":"Saleh","year":"2020","journal-title":"Cancer Med"},{"key":"2024050215465234100_b28","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1002\/cncr.25226","article-title":"Long-term outcome in localized extranodal mucosa-associated lymphoid tissue lymphomas treated with radiotherapy","volume":"116","author":"Goda","year":"2010","journal-title":"Cancer"},{"key":"2024050215465234100_b29","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.ijrobp.2013.11.225","article-title":"Radiation therapy administration and survival in stage I\/II extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue","volume":"88","author":"Olszewski","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["The British Journal of Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjr\/article-pdf\/94\/1123\/20210012\/57374203\/bjr.20210012.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjr\/article-pdf\/94\/1123\/20210012\/57374203\/bjr.20210012.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T17:47:59Z","timestamp":1714672079000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjr\/article\/doi\/10.1259\/bjr.20210012\/7455657"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,16]]},"references-count":29,"journal-issue":{"issue":"1123","published-online":{"date-parts":[[2021,6,16]]},"published-print":{"date-parts":[[2021,7,1]]}},"URL":"https:\/\/doi.org\/10.1259\/bjr.20210012","relation":{},"ISSN":["0007-1285","1748-880X"],"issn-type":[{"value":"0007-1285","type":"print"},{"value":"1748-880X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,7,1]]},"published":{"date-parts":[[2021,6,16]]},"article-number":"20210012"}}